Products powered by Novavax’s Technology Platform
Novavax’s legacy of innovation impacts the lives of millions through the following products currently on the market
Nuvaxovid™ (COVID-19 Vaccine)
Built on Novavax’s proprietary recombinant nanoparticle and Matrix-M® adjuvant technology platform, Novavax developed this vaccine in response to the COVID-19 global pandemic and is the only protein-based, non-mRNA option for those most at risk. With approvals in countries around the world, this vaccine is now commercialized by our partners Sanofi, Takeda and the Serum Institute of India.
R21/Matrix-M® (Malaria Vaccine)
Developed in partnership between the Serum Institute of India and Oxford University, R21/Matrix-M® is powered by our adjuvant technology for the prevention of malaria and embodies our mission of collaborating to tackle some of the world’s most significant health challenges. This vaccine is WHO-prequalified and distributed by UNICEF in endemic regions to provide another tool to help protect hundreds of thousands of children each year.
Pipeline
We are advancing a pipeline of high-value assets targeting areas with unmet medical needs, strong scientific rationale and significant commercial potential.
Partnerships
Our strategy is to create partnership and collaboration opportunities to maximize the impact and value of our pipeline assets and Matrix-M alone.